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HIV Pr55gag has in the absence of other viral components the capacity to self assemble in budding noninfectious virus-like
particles (VLP). The immunological spectrum of the HIV-1IIIB gag-derived VLP was expanded either by stable anchoring of
chimeric modified gp120 on the surface of the VLP (type 1) or by replacing sequences of the Pr55gag precursor by the V3 loop
and a linear portion of the CD4 binding domain (type 2). This noninfectious antigen delivery system was evaluated for
immunogenicity and efficacy in rhesus macaques without adjuvants. Intramuscular immunization with both types of VLP
induced high titers of gag-specific antibodies ranging from 1/8000 to 1/510,000 for type 1 VLP and from 1/4000 to 1/16,000
for type 2 VLP. Only animals immunized with type 1 VLP developed substantial endpoint titers of env-specific antibodies
(1/2000–1/32,000) with a neutralizing capacity at serum dilutions of 1/32–1/128. Gag- and env-specific cytotoxic T lympho-
cyte (CTL) activity was induced by both types of VLP at similar levels. Four weeks after the last immunization animals were
challenged intravenously with 20 MID50 of the cell free homologous envelope simian/HIV-1IIIB chimeric challenge stock.
Despite HIV-1-specific neutralizing and CTL responses, all vaccinated animals became infected. © 1998 Academic Press
INTRODUCTION
Despite an extensive knowledge of structure, host
interaction, and pathogenesis of HIV-1, efforts to achieve
an effective prophylactic or therapeutic vaccine have to
date not been successful. To strengthen the approach to
AIDS vaccine development a better understanding of the
immune correlates of protection from HIV infection are
needed (Haynes et al., 1996; Heeney et al., 1997). HIV-1
vaccine efficacy studies in chimpanzees have demon-
strated that the titer of virus neutralizing (VN) antibodies
correlates with protection from a homologous cell-free
infection (Berman et al., 1990; Bruck et al., 1994; ten Haaft
et al., 1995). HIV-infected individuals generally develop
strong humoral responses to HIV. However, these re-
sponses ultimately fail to protect against disease devel-
opment, in part perhaps due to antigenic variability, im-
mune escape, and the intracellular nature of HIV. In this
context, many vaccine efforts are now focused on induc-
tion of HIV-specific cytotoxic T lymphocyte (CTL) as well
as neutralizing antibody responses. In addition to hu-
moral activity, vigorous and persistent CTL responses
are observed in asymptomatic HIV-infected individuals
(Levy, 1993). However, the development of HIV-specific
CTL early after infection has been shown to coincide
with the decline of viremia (Borrow et al., 1994; Koup et
al., 1994). In several cases, including experimental SIV-
infected rhesus macaques, specific cellular immune re-
sponses have been detected prior to seroconversion and
before the detection of VN antibodies (Yasutomi et al.,
1993; Safrit et al., 1994; Gallimore et al., 1995). Hence CTL
responses may play an important role in clearing in-
fected cells, reducing intracellular virus loads, and pre-
venting or slowing disease progression (Carmichael et
al., 1993; Klein et al., 1995; Rinaldo et al., 1995). CTLs are
directed against various conserved epitopes from virtu-
ally any viral protein. By eliminating infected cells they
have the potential to prevent the early dissemination of
infection. Recently, vaccine strategies to specifically in-
duce CTL responses have been proposed. CTLs are
unfortunately difficult to stimulate by subunit vaccine
approaches, due to the requirement of endogenous pro-
cessing of intracellularly synthesized proteins for pre-
sentation in the context of MHC class I molecules. How-
ever, using specific adjuvant formulations and/or antigen
presentation forms, exogenous antigens have been
shown to prime for CTL responses in vivo (Deres et al.,
1989; Newman et al., 1992; Zhou et al., 1992; Bourgault et
al., 1994; Lipford et al., 1994; Scalzo et al., 1995).
Assembly of HIV, like other members of the lentivirus
genus of retroviruses, occurs by a budding process at
the cellular plasma membrane. In several studies it was
demonstrated that the HIV-1 Pr55gag precursor ex-
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pressed in the absence of other viral components is
self-sufficient to form noninfectious virus-like particles
(VLP) that are released from various eukaryotic cells by
budding (Gheysen et al., 1989; Haffar et al., 1990; Shioda
et al., 1990; Smith et al., 1990; Wills et al., 1991; Wagner et
al., 1992, 1994). Based on this capacity, an autologous,
nonreplicating, safe, and immunogenic antigen delivery
system was developed. The antigenicity of the Pr55gag
precursor-based VLP was extended by the gp120 exter-
nal envelope protein firmly incorporated in large quanti-
ties at the outer surface of the particle by a heterologous
Epstein–Barr virus gp220/350-derived transmembrane
domain (hybrid Pr55gag/env VLP) (Wagner et al., 1995;
Deml et al., 1997a) or by size-limited linear epitopes
inserted into the particle forming polyprotein (chimeric
VLP) (Wagner et al., 1994, 1996). It has been shown
previously that both types of particles are highly immu-
nogenic in rodents. Consistent anti-Pr55gag as well as
anti-env antibody responses were generated in complete
absence of an additional adjuvant. A strong VN antibody
activity was only observed in animals immunized with
hybrid Pr55gag/env VLP, whereas CTLs were induced by
both type of VLPs (Deml et al., 1997b).
In this study we compared the ability of hybrid and
chimeric HIV-1 envelope-expressing VLPs to induce VN
antibodies and CTLs in rhesus macaques. Efficacy of
both types of vaccine candidates was evaluated by chal-
lenge with chimeric simian/human immunodeficiency vi-
rus that expressed the homologous env gene from HIV-
1IIIB in place of SIVenv in the SIVmac239 molecular clone.
RESULTS
Antibody responses induced by hybrid and
chimeric VLP
Rhesus monkeys were immunized intramuscularly in
the absence of adjuvant with either type 1 hybrid Pr55gag/
env VLP expressing the complete gp120 at the outer
surface of the particle (group A) or type 2 chimeric VLP
expressing the inserted V3 domain and CD4 binding
region of gp120 (group B). Previous studies in rodents
demonstrated that both types of VLP exhibited intrinsic
adjuvant properties for generating strong humoral and
cell-mediated immune responses. Absorption to alumi-
num hydroxide did not improve humoral responses, but
completely abrogated the immunogenicity of type 2 VLP
for CTL (Wagner et al., 1996; Deml et al., 1997b). All
animals in groups A and B received a priming immuni-
zation of 100 mg/dose at week 0 followed by two booster
immunizations of the same dose at weeks 6 and 16. The
four control animals of group C were nonimmunized.
Antibody titers to p24 and gp120 were measured by
ELISA. Immunization with both types of VLP induced
gag-specific antibodies after the primary immunization
(Fig. 1A). An increase in gag-specific antibodies was
observed in both groups after the booster immunization
at week 6. The highest gag-specific antibody titers were
observed in group A compared to group B and ranged
from 1/8000 to 1/510,000 for group A and from 1/4000 to
1/16,000 for group B. env-specific antibody titers devel-
oped in immunized animals are depicted in Fig. 1B. Only
animals of group A developed substantial endpoint titers
of env-specific antibodies (1/2000-1/64,000). env-specific
antibody titers had already developed 2 to 6 weeks after
the primary immunization and increased after the
booster immunization. Low titers of V3-specific antibod-
ies were only detected in animal 2DG of group A, which
had the highest env-specific antibody titer after the first
booster immunization (data not shown). Substantial titers
of VN antibodies, assessed at different time points in-
cluding 2 and 4 weeks after the second booster immu-
nization, were also exclusively detected in animals of
group A and reached endpoint titers of 1/32–128 (Fig.
1C). In the control group C, low serum antibody titers to
gag (Fig. 1A) and env (Fig. 1B) were detected in monkeys
9246 and 9231 at more than one time point. These low-
level gag-reactive responses in naive animals prechal-
lenge may possibly be due to cross-reactivity with other
retrovirus-related endogenous antigens (Haist et al.,
1992).
Hybrid and chimeric VLP induced CTL responses
Two weeks after the first booster immunization (week
8). To measure vaccine-induced CTL activity, peripheral
blood mononuclear cells (PBMC) were in vitro restimu-
lated with autologous stimulator cells. Stimulator cells
were Con A-activated and IL-2-expanded PBMC pulsed
with pools of peptides representing 10 sequential amino
acids overlapping 20 mers of the entire HIV-1 p24 or
gp120. PBMC from rhesus monkeys vaccinated with type
1 hybrid Pr55gag/env VLP (group A) were assessed for
their ability to lyse autologous B-LCL pulsed with sub-
pools of peptides representing HIV-1 gag (A, B, C), or env
(D, E, F, G) proteins. PBMC from monkeys vaccinated
with type 2 chimeric Pr55gag/V3/CD4 BR VLP (group B)
were also tested against the subpools of the entire gag
(A, B, C) and against subpools of overlapping peptides
representing the V3 (D1), and CD4BR (E1) region of env.
Unpulsed autologous B-LCL were used as negative con-
trol target cells. Cytotoxicity was considered positive
when lysis of pulsed targets exceeded lysis of unpulsed
targets by 10%.
CTL activity measured 2 weeks after the first booster
immunization (week 8) is summarized in Table 1. PBMC
from one of four monkeys in group A and one of four in
group B demonstrated HIV-specific cytotoxicity 2 weeks
after the first booster immunization. PBMC from control
animals in group C stimulated and tested in the same
way as PBMC from group A were negative in this assay
(data not shown). Monkey C93 (group A) lysed target
cells pulsed with pool A of gag. The percentage specific
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lysis (corrected for the lysis of unpulsed targets) at an E:T
ratio of 40:1, 20:1, and 10:1 was 10, 6, and 6%, respec-
tively. Monkey A98 (group B) lysed target cells pulsed
with pool A of gag and pool E1 representing the CD4
binding region of env. The percentage specific lysis at an
E:T ratio of 40:1, 20:1, and 10:1 of pool A pulsed targets
was 31, 38, and 24%, respectively, and of pool E1 was 20,
23, and 17%, respectively.
Two weeks after the second booster immunization
(week 18). PBMC from two of four monkeys in group A
and two of three analyzed monkeys in group B demon-
strated HIV-1-specific cytotoxicity 2 weeks after the sec-
ond booster immunization. The results of group A and
group B are summarized in Table 1. Monkey 2DG (group
A) lysed target cells pulsed with pools A, B, and C of gag
and pool D of env. The percentage specific lysis at an E:T
FIG. 1. Humoral immune responses in groups A, B and C. (A–D) Titers of p24 (A)-, gp120 (B)-, and gp41 (D)-specific serum antibodies and VN
antibody titers (C) (.90% neutralization of HIV-1IIIB) at different time points before and after challenge were determined as described under Materials
and Methods. Weeks of immunization are indicated with open arrows (3) and the week of challenge is indicated with a closed arrow (–). (A–C)
Group A monkeys are 2DG (F), C93 (E), 9266 (n), and 9261 (); Group B monkeys are 9259 (F), A98 (E), A91 (n), and 9260 (); and Group C monkeys
are 9246 (F), 2DI (E), 9231 (n), and D96 (). (C) Substantial titers of VN antibodies prechallenge were exclusively detected in animals of group A (2DG
(n), C93 (h), 9266 ( ), 9261 ( )).
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ratio of 40:1, 20:1, and 10:1 of pool A was 11, 10, and 8%,
respectively; of pool B, 15, 14, and 13%, respectively; of
pool C, 11, 13, and 6%, respectively; and of pool D, 16, 11,
and 9%, respectively. Monkey 9266 (group A) lysed tar-
gets pulsed with pool A. The percentage specific lysis at
an E:T ratio of 40:1, 20:1, and 10:1 was 18, 10, and 11%,
respectively. Monkey C93 of group A, which demon-
strated specific lysis of pool A pulsed target cells after
the second immunization, was scored negative after the
third immunization. However, PBMC of this monkey dem-
onstrated a high background lysis of unpulsed target
cells at this time point (data not shown). Monkey 9259
(group B) lysed target cells pulsed with pool A. The
percentage specific lysis at an E:T ratio of 40:1, 20:1, and
10:1 was 12, 3, and 14%, respectively. Monkey A98 (group
B) lysed target cells pulsed with pool A, as had been
found after the second immunization. The percentage
specific lysis at an E:T ratio of 20:1, 10:1, and 5:1 was 18,
19, and 16%, respectively.
Challenge and quantitative virus isolation
Four weeks following the second booster immuniza-
tion (week 20), all animals were challenged with 20
MID50 of cell free homologous envelope simian/HIV-1IIIB
chimeric stock SHIV(IIIB). All vaccinated and control an-
imals became infected, as was shown by quantitative
virus isolation. The numbers of SHIV(IIIB)-infected cells
per 106 PBMC are depicted in Fig. 2. In controls, the
number of SHIV-infected cells in circulation reached a
maximum 2, and in one case, 4, weeks after challenge.
Neither immunization regimen protected the animals
from infection. However, a tendency for faster clearance
of the initial peak was apparent in group A compared to
the two other groups. However, the differences in virus
load did not reach significance.
Epitope-specific CTL responses before (week 8) and
after (week 30) challenge
PBMC of monkey A98 demonstrated the most pro-
nounced CTL activity with specificity for pool A of gag
(HIV) and pool E1 representing the CD4 binding region of
env (HIV) after the first booster immunization. After the
second booster immunization gag-specific CTL activity
persisted, but the env-specific CTL activity was below
detectable levels. This suggested that the third immuni-
zation did not enhance CTL immunity. To analyze
whether challenge and subsequent infection with SHIV
may have modulated the CTL activity of animal A98,
PBMC isolated at 10 weeks after the challenge (week 30)
were tested for env (HIV-1)-, p24gag/HIV-, and p26gag/SIV-
specific CTL responses. At this time point after challenge
PBMC of monkey A98 demonstrated CTL activity with
specificity for pool E1 of env (HIV) and pool A1 of p26gag
derived from SIV (data not shown). Specificity for p24gag
of HIV-1 was not detected in circulation after the chal-
lenge, indicative of an absence of cross-reactivity be-
tween p24gag of HIV-1 and p26gag of SIV.
To define more precisely the fine specificity of CTL
responses before and after challenge, T cell cultures
were analyzed using the single peptides of pool A (the
first eight 10 amino acids overlapping 20 mers from
p24gag of HIV) and E1 (three 10 amino acids overlapping
TABLE 1
CTL Response 2 Weeks after the Firsta/Secondb Booster Immunization
Group Monkey
% Specific lysis of targets pulsed with peptide poolsd
A B C D/D1c E/E1c F G
A 2DG 1a/11b 4/15 1/11 1/16 ,1/8 8/,1 7/7
C93 10/,1 3/,1 ,1/,1 1/,1 1/,1 ,1/,1 2/,1
9266 ,1/18 ,1/,1 ,1/,1 2/3 3/,1 ,1/1 4/3
9261 ,1/3 6/0 ,1/1 1/,1 1/8 5/5 ,1/2
B 9259 ,1/12 ,1/,1 ,1/,1 0/3 8/,1 ndc nd
A98 31/18 9/,1 0/,1 3/,1 20/,1 nd nd
A91 ,1/,1 7/,1 2/,1 3/3 ,1/0 nd nd
9260 ,1/nd 9/nd ,1/nd 6/nd ,1/nd nd nd
Note. Effector cells were prepared by costimulation with autologous peptide pulsed ConA blasts, as described under Materials and Methods.
Cytotoxicity was assayed with autologous B-LCL pulsed with pools of peptides. The peptide pools used to analyze specific cytotoxicity are designated
A, B, C (p24), D, E, F, G (gp120), D1 (V3), and E1 (CD4BR). Pool A contains the MRC overlapping peptides ADP 788/17-22 (gag); pool D, the peptides
740/1-12 (env); pool E, the peptides ADP 740/13-24 (env); pool F, the peptides ADP 740/25-37 (gp120); pool G, the peptides ADP 740/38-47 (gp120); pool
D1, the peptides ADP 740/27-30 (V3); and pool E1, the peptides ADP 740/39-41 (CD4BR).
a CTL response 2 weeks after the first booster immunization.
b CTL response 2 weeks after the second booster immunization.
c Animals of group B were analyzed for lysis of D1 and E1.
d The percentage specific lysis is expressed as percentage of 51Cr release of pulsed targets minus the percentage of 51Cr release of unpulsed
targets. Effector to target ratio was 40:1. A specific lysis equal or above 10% was considered as positive and is expressed in boldface.
e nd, not determined.
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20 mers, spanning the CD4 binding region of HIV). After
challenge peptides representing pool A1 of p26gag de-
rived from SIV (the first six 10 amino acids overlapping 20
mers from p26gag of SIV) were included in the epitope
mapping. Epitope-specific responses before and after
challenge are depicted in Figs. 3A and 3B, respectively.
Before challenge the gag (HIV)-stimulated T cells dem-
onstrated specificity for peptide ADP 788/3 (amino acids:
NAWVKVVEEKAFSPEVIPMF) of p24gag (HIV) and the env
stimulated T cells for peptide ADP 740/41 (amino acids:
KAMYAPPISGQIRCSSNITG) of gp120 (HIV). After chal-
lenge the specificity for ADP 788/3 of p24 (HIV) was
undetectable, whereas specificity for peptide ADP 740/41
of gp120 persisted. The gag (SIV)-stimulated T cells dem-
onstrated specificity for peptide ADP 714/5 (amino acids:
ALSEGCTPYDINQMLNCVGD) of p26gag (SIV). After chal-
FIG. 3. Peptide-specificity of the gag- and env-specific CTL re-
sponses of PBMC cocultures from monkey A98 (group B). (A) Two
weeks after the second immunization (week 8). (B) 10 weeks after the
challenge (week 30). P24gag-stimulated PBMC cocultures were tested
for specific CTL activity using autologous B-LCL pulsed with pool A and
its single peptides from p24.1 up to and including p24.8. env-stimulated
PBMC cocultures were tested using peptide pool E1 and its single
peptides p39, p40, and p41 and p26gag-stimulated PBMC cocultures
were tested using peptide pool A1 and its single peptides p26.1 up to
and including p26.6. Unpulsed B-LCL were used as negative control
targets. Specific lysis of 10% above the background was considered as
positive.
FIG. 2. The number of SHIVIIIB-infected cells per 10
6 PBMC. The virus
titer was determined in a quantitative virus isolation (QVI), as described
under Materials and Methods. The first QVI was performed 2 weeks
after the challenge. Group A monkeys, 2DG (F), C93 (F), 9266 (n), and
9261 (). Group B monkeys, 9259 (F), A98 (E), A91 (n), and 9260 ().
Group C monkeys, 9246 (F), 2DI (E), 9231 (n), and D96 ().
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lenge no CTL cross-reactivity between gag derived from
HIV and SIV was observed (data not shown).
SIV- and HIV-specific antibody titers after challenge
Antibody titers to SIVp27, HIVp24, gp120, and gp41
were measured at weeks 20 (challenge), 22, 28, and 32
by ELISA. SIVp26-specific antibody titers, presumably
due to a strong cross-reactivity, closely paralleled the
course of HIVp24 titers (Fig. 1A). In group B and naive
control animals (group C) gag-specific antibody titers
increased following SHIV infection from 1/4000–1/16,000
to 1/16,000–1/512,000 in group B and from nondetectable
levels to 1/8000–1/16,000 in group C (Fig. 1A). In group A,
which developed the highest antibody titers before chal-
lenge, gag-specific antibody titers did not alter substan-
tially from the prechallenge values (Fig. 1A). gp120-spe-
cific antibodies were boosted in all animals and reached
comparable titers in all groups, ranging from 1/32,000 to
1/1,024,000 in group A, from 1/128,000 to 1/256,000 in
group B, and from 1/64,000 to 1/512,000 in group C (Fig.
1B). As an independent marker for seroconversion, anti-
body titers to HIVgp41, which was not included in the
immunogen (but is part of the challenge virus), were
analyzed throughout the period of immunizations, at
challenge (week 20) and 2, 8, and 12 weeks thereafter
(Fig. 1D). gp41-specific antibodies could not be detected
at challenge but developed 2 to 8 weeks after challenge
in all infected animals and reached titers of 1/16,000–1/
512,000. VN antibodies were detected in all but one
(M-A93) animal to relatively equal end point titers of
1/128–1/256 12 weeks after challenge (Fig. 1C).
DISCUSSION
This study was designed to compare immunogenicity
and efficacy of 2 different HIV-1 virus-like Pr55gag particle
vaccine strategies in the absence of adjuvants in Ma-
caca mulatta. The first preparation consisted of the HIV-1
Pr55gag VLP carrying a stable anchored gp120 on its
surface (type 1 hybrid Pr55gag/env VLP) (Wagner et al.,
1995; Deml et al., 1997a). The second preparation con-
sisted of a HIV-1 Pr55gag polyprotein precursor with in-
sertions of selected env sequences of the V3 domain and
the linear stretch of the CD4-binding region (type 2 chi-
meric Pr55gag/V3/CD4 BR VLP) (Wagner et al., 1994,
1996).
In rhesus monkeys both types of VLP induced humoral
as well as cellular immune responses to HIV-1 gag and
env antigens. Type 1 hybrid VLP expressing gp120 on its
surface proved to induce the highest serum antibody
titers to gag and env. In addition, animals immunized with
type 1 VLP developed substantial VN antibody titers
reaching values comparable to those previously mea-
sured in rabbits (Wagner et al., 1995; Deml et al., 1997b).
Insertion of relevant env epitopes (V3 and CD4BR) into
the gag precursor (type 2 chimeric VLP) induced low
titers of env-specific antibodies with no VN activity, which
is in accordance with the results previously obtained in
rabbits (Wagner et al., 1996). Immunization with type 2
VLP did not improve antibody responses to the inserted
domains of env (data not shown), but rather reduced
humoral responses to capsid protein. This may suggest
that B cell epitopes were lost due to conformational
changes induced by the insertions in the gag precursor.
Both types of VLP were previously shown to induce a
MHC class-I restricted CTL response to a well-charac-
terized epitope located in the V3 loop of gp120 previously
defined in BALB/c mice (Takahashi et al., 1988; Wagner
et al., 1993, 1996). No or only minor differences between
the two types of VLPs were found in the induction of CTL
responses in rhesus macaques. In principle, both VLP
preparations were demonstrated to be capable of induc-
ing gag- and/or env-specific CTLs in absence of adju-
vants, although most of the observed responses were
sporadic and not durable. However, responses to gag
were more frequently observed than responses to env.
env-specific cytotoxicity was most pronounced in the
type 2 VLP-immunized animal A98 of group B and was
shown to recognize an epitope located in the CD4 bind-
ing region. CTLs were not detected in all immunized
monkeys, probably due to the outbred nature of the
animals and their polymorphic MHC alleles. Although
HIV-1 env-specific CTL responses have been measured
in SHIV-infected rhesus macaques, HIV-1-specific CTL
epitopes and MHC restriction have not yet been de-
scribed (Voss et al., 1995). Due to logistic constraints,
analysis of epitope-specific responses, as was per-
formed in mice, was not feasible in this rhesus macaque
study. However, studies are in progress to define more
precisely the gag- and env-specific CTL epitopes and
their MHC restriction in this study. Since CTL activity
was assayed using pools of overlapping peptides, it
may be speculated that relevant naturally processed and
presented epitopes may have been missed with this
protocol.
Immunization with both types of VLP did not induce
protection from an intravenous cell free challenge with
the chimeric SHIV. In this partially homologous SHIV
challenge model only protection from env-mediated im-
munity could be evaluated. The gag protein of SHIV is
derived from SIV and only partial cross-reactivity of anti
HIV-1 gag immunity could have been expected. Efforts to
study the fine specificity of the gag-specific CTL re-
sponse in animal A98 did not reveal any detectable
cross-reactivity between HIV-1 and SIV gag epitopes.
Data were suggestive of possibly enhanced clearance of
viremia observed in type 1 VLP-immunized monkeys,
which might correlate with the titers of env and VN serum
antibodies.
The role of vaccine-induced SIV-specific CTL in sup-
pression of SIV replication and protection from infection
is still controversial. Several studies provided evidence
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that SIV-specific CTL responses correlate with a lower
virus load (Venet et al., 1992; Bourgault et al., 1993). In a
previous vaccine study protection from a cell-associated
SIV challenge was shown to be associated with the MHC
class I molecule Mamu-A26, which was shared between
the protected animals and the donor of the challenge
virus (Heeney et al., 1994). Although SIV-specific CTLs
were only detected after challenge, a role for CTLs in the
recognition of SIV-infected donor cells in a MHC-re-
stricted manner was suggested. A correlation between
the vaccine induced SIV nef-specific CTL precursor fre-
quency and clearance of the initial viremia after cell free
SIV challenge was observed by Gallimore et al. (1995) in
a high-risk population, suggesting that strong vaccine-
induced CTL responses could protect against HIV infec-
tion. On the other hand vaccine studies in which no
protection from SIV challenge was achieved despite the
occurrence of vaccine-primed CTL activity are as com-
mon as those describing a good correlation (Hulskotte et
al., 1995; Yasutomi et al., 1995). Hence the quality and the
magnitude as well as the durability of cellular immune
responses may account for the contradictory results in
this field and contribute toward explaining the lack of
protection despite the presence of gag-specific cells
detected in each of two animals of groups A and B.
CD81 T cells may also function as MHC-unrestricted,
nonlytic suppressor cells in HIV replication (Walker et al.,
1986; Mackewicz et al., 1992). Similarities in HIV inhibi-
tory effects of the CD8 suppressor factor, the three che-
mokines, RANTES, MIP-1a, and MIP-1ß, and IL-16 have
been reported (Baier et al., 1995; Cocchi et al., 1995).
Recently it has been shown that, in the absence of
detectable CTL activity, CD8 suppressor factor and the
chemokines RANTES and MIP-1ß were associated with
protection from rectal SIV challenge, suggesting that
these chemokines were induced by the vaccine strategy
(Lehner et al., 1996). This intriguing observation may
imply that in addition to specific antiviral immunity non-
specific immune responses should be evaluated in HIV/
SIV vaccine immunogenicity and efficacy studies.
In summary, gag precursor-based VLP have been
shown to be efficient carriers and to provide humoral as
well as cellular immunity to the external envelope protein
gp120 of HIV-1. However, the env-specific immunity in-
duced was not sufficient to protect animals from a SHIV
challenge. The role of gag-mediated immunity was pos-
sibly due to a limited cross-reactivity between HIV- and
SIV-specific CTLs not apparent in this setting. Studies
are now in progress in which VLPs destined for evalua-
tion of VLP in a pathogenic SHIV model are based on the
SIV gag precursor. In order to enhance the immunoge-
nicity of VLP for inducing broadly cross-neutralizing an-
tibodies and a durable CTL response, the next genera-
tion of VLP will be produced in mammalian cells to
ensure proper glycosylation, folding, and oligomerization
of the env proteins and administered in the presence of
a Th1 stimulating adjuvant.
MATERIALS AND METHODS
Animals and immunizations
Twelve rhesus monkeys (M. mulatta) were selected for
this study and separated into three groups of four ani-
mals each. Group A consisted of the animals 2DG, C93,
9266, and 9261, which were immunized with hybrid
Pr55gag/env VLP expressing gp120 derived from HIV-1IIIB
incorporated at the outer surface of the particle. Group B
consisted of the animals 9259, A98, A91, and 9260, which
were immunized with chimeric Pr55gag VLP expressing
the third variable domain V3 and the CD4-binding do-
main of the envelope external glycoprotein gp120 of
HIV-1IIIB inserted into the gag gene to replace amino
acids 436–471. Group C consisted of the animals 9246,
2DI, 9231, and D96 and served as a nonimmunized neg-
ative control. Immunizations were performed at three
time points. Booster immunizations were given at 6 and
16 weeks after the first immunization. A bolus injection of
100-mg adjuvant free VLP preparations in a final volume
of 1 ml was given in a single site in the back of the upper
left leg.
Production, purification, and characterization of VLPs
Construction of the recombinant baculoviruses (Autog-
rapha california nuclear polyhedrosis virus; AcNPV) en-
coding the complete HIV-1 gag (Pr55gag) gene, the chi-
meric Pr55gag genes expressing the V3 and CD4 binding
region of gp120, and the gp120 Epstein–Barr virus trans-
membrane domain gp220/350 fusion protein have previ-
ously been described in detail (Wagner et al., 1996; Deml
et al., 1997a). Large-scale production of chimeric virus-
like particles was accomplished in High Five insect cells
under serum free culture conditions, as described pre-
viously (Wagner et al., 1996; Deml et al., 1997a). Briefly, to
produce type 1 VLPs, High Five insect cells were co-
infected with AcPr55gag expressing the complete HIV-
1IIIB Pr55
gag precursor (Wagner et al., 1992) and
Acgp120/TM expressing the extracellular portion of the
HIV glycoprotein fused to a heterologous transmem-
brane domain (MOI of 10 per cell for each virus). This
transmembrane domain was derived from the EBV
gp220/350 and has been demonstrated to mediate sta-
ble anchoring of the chimeric gp120 at the surface of the
VLPs to an extent which exceeded that of full-length
gp160 by a factor of 10 (Deml et al., 1997a). In order
to produce type 2 VLPs, High Five insect cells were
infected with AcPr55V3-4 or, alternatively, with
AcPr55CD4BR-4, whereas either the V3-loop (amino ac-
ids 296–332) or a linear portion of the CD4 binding
domain (amino acids 403–458) replaced amino acids
436–471 within the gag precursor (MOI of 10 per cell).
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Three days postinfection, cell culture supernatants were
harvested. A concentration of VLP from culture superna-
tant (3300g) was achieved as described (Wagner et al.,
1996). The concentrated material (2-ml aliquots) was
layered onto a 12-ml 10–60% sucrose gradient in 10 mM
phosphate buffer, pH 7.5, containing 0.15 M NaCl and
centrifuged at 100,000g for 20 h at 4°C. Fractions (0.5 ml)
were collected and diluted by PBS and VLP were pel-
leted at 16,000 rpm for 40 min at 4°C in an Eppendorf
centrifuge. The antigen preparations were resuspended
in 200 ml 20 mM Tris–HCl, pH 7.5, 150 mM NaCl, 2 mM
EDTA and analyzed by conventional Western blot analy-
sis by using gag- and env-specific monoclonal antibod-
ies following separation of the proteins on a denaturing
12% SDS–PAGE. Antigen from all fractions was quantified
exactly using a commercial p24-specific antigen capture
assay (Abbott, USA). Stable anchoring of gp120/TM on
the surface of the VLPs was additionally proven by im-
munogold labeling using a gp120 monoclonal antibody.
Fractions that were—according to negative stain elec-
tron microscopical examination—almost free of contam-
inating AcNPVs were pooled and used for the immuni-
zations.
Peptides and recombinant proteins
Overlapping peptides spanning the entire gp120 (HIV-
1IIIB), p24
gag (HIV-1 SF2), and p26gag (SIV) region were
obtained from the MRC AIDS Reagent project. env (ADP
740) consisted of 47, p24gag (ADP 788) of 22, and p26gag
(ADP 714) of 22 20 mers overlapping by 10 amino acids.
Recombinant gp120 (IIIB) was kindly provided by Genen-
tech Inc. (San Francisco, USA). Gag proteins were pro-
duced and purified as described previously. Gp41 was
kindly provided by Mikrogen GmbH (Munich, Germany)
(Wagner et al., 1996).
ELISAs and VN assay
Gp120- and p24-specific antibodies were analyzed in
plasma collected before and postchallenge and at reg-
ular time points after each immunization by ELISA, as
previously described (Wagner et al., 1996). Positive reac-
tions were visualized with 0.1% hydrogen peroxide in the
presence of 39,3-diaminobenzidine tetrahydrochloride
and stopped after 10 min with 1 M H2SO4. Absorbance
was determined at 492 nm and reactions were consid-
ered positive if they exceeded the mean absorbance of
equal dilutions of preimmune sera by a factor of three.
VN antibodies were determined in sera collected at dif-
ferent time points before (week 0) and after immunization
(weeks 2, 6, 8, 12, 16, and 18), at the day of challenge
(week 20), and 2, 8, and 12 weeks after challenge, as
described previously (Wagner et al., 1996). Sera were
heat inactivated at 56°C for 30 min. Serial twofold dilu-
tions of each serum were prepared in triplicate and
incubated with 50 tissue culture infectious doses
(TCID50) of HIV-1LAI for 1 h at 37°C. The virus-serum
mixture was then added to 5 3 104 MT4 cells. Following
an incubation at 37°C, 5% CO2 in a humid atmosphere for
6 days, cell cultures were examined for virus release by
a commercial p24 sandwich assay (Abbott, USA). The
neutralizing titer was calculated as the reciprocal of the
serum dilution that resulted in .90% reduction of the p24
synthesis compared to the equivalent dilution of the
preimmune serum from the same animal.
Generation of CTL effector cells
Effector cells were generated from LSM (Organon-
Teknica) density gradient isolated PBMC. To activate
antigen-specific cytotoxic effector cells, PBMC were
cocultured with autologous Con A (5 mg/ml)-stimulated,
IL-2-expanded, and peptide-pulsed T cell blasts (stimu-
lator cells). To prepare stimulator cells, Con A T cell
blasts were incubated with overlapping peptide pools
(each peptide at a 4–8 mg/ml concentration) of complete
env (47 peptides), gag (22 peptides), or peptides span-
ning the V3 (peptides ADP 740/27-30) and CD4 binding
region (peptides ADP 740/39-41) of env for 3 h at 37°C
and 5% CO2. After incubation, stimulator cells were irra-
diated with 3000 rad. Stimulator cells and 15 3 106 fresh
isolated PBMC were cocultured at a ratio of 1-0,5:1 in 3
ml RPMI 1640 (GIBCO) supplemented with l-glutamine (2
mM), penicillin, streptomycin, and 10% FCS in three wells
(1 ml/well) of a 24-well plate. After 48 h these cultures
were supplemented with IL-2 at a concentration of 20
U/ml. Cultures were regularly fed with culture medium
containing IL-2 during the coculture period of 12–14
days. Before assaying cytotoxic effector cells, dead cells
were removed by LSM density gradient centrifugation.
Cytotoxicity assay
Target cells were autologous Herpesvirus papio im-
mortalized B-lymphoblastoid cell lines (B-LCL) labeled
with 0.150 mCi Na2 CrO4 for 1 h, then pulsed with pools
of peptides at 25 mg/ml per peptide for 1 h at 37°C,
followed by a 16-h peptide incubation period at 2.5 mg/ml
per peptide. Unpulsed B-LCL were used as controls.
Subsequently, target cells were washed and plated at
5 3 103 cells/well in 96-well U-shaped plates together
with effector cells at various effector/target ratios. After
5 h incubation at 37°C supernatants were harvested and
counted in a gamma counter. Percentages of specific
51Cr release were calculated as 1003 (experimental re-
lease 2 spontaneous release):(maximum release 2
spontaneous release). All experimental values were de-
termined in triplicate or duplicate and maximum and
spontaneous releases were performed in quadruplicate.
Responses of 10% or more above specific lysis of control
targets were scored as positive.
The peptide pools used to analyze specific cytotoxicity
were designated A, B, C (p24gag of HIV), A1, B1, C1 (p26gag
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of SIV) D, E, F, G (gp120 of HIV), D1, and E1 (V3 and CD4
BR). Pool A contains the MRC overlapping peptides ADP
788/1–8 (p24), pool B the peptides ADP 788/9–16 (p24),
pool C the peptides ADP 788/17–22 (p24), pool A1 the
peptides ADP 714/1–6 (p26), pool B1 the peptides ADP
714/7–12 (p26), pool C1 the peptides ADP 714/14–22
(p26), pool D the peptides ADP 740/1–12 (gp120), pool E
the peptides ADP 740/13–24 (gp120), pool F the peptides
ADP 740/25–37 (gp120), pool G the peptides ADP 740/
38–47 (gp120), pool D1 the peptides ADP 740/27–30
(gp120), and pool E1 the peptides ADP 740/39–41 (gp120).
SHIV challenge
The chimeric virus used in this study was obtained
from Virus Research Institute (VRI, Cambridge, USA).
This virus expresses the gag, pol, vif, vpr, and nef pro-
teins of SIVmac239 (nef open) and the tat, rev, vpu, and
env proteins of HIV-1 (HXBc2) (Li et al., 1992). The virus
stock was propagated on rhesus PBMC and the titer was
determined by titration in CEMx174 cells. This virus stock
had a TCID50 of 4 3 10
3. The animals were inoculated
intravenously with 80 TCID50, which is approximately
equivalent to 20 MID50.
Virus isolation
At 2-weeks intervals for 10 weeks following SHIV(IIIB)
challenge, infection of PBMC was monitored by quanti-
tative virus isolation. From each time point, 12 consecu-
tive threefold dilutions of PBMC, starting with 106 PBMC,
were added to 5 3 105 C8166 T cells in duplicate and
cocultured for 3 weeks. Once a week the wells were
scored for the presence of syncytia. To confirm the virus
load, culture supernatants were analyzed for the pres-
ence of p24 by antigen capture (Coulter, USA).
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